miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer.
miR-129 as a novel therapeutic target and biomarker in gastrointestinal cancer.
复制标题
DOI：
10.2147/ott.s65548
复制
发表时间：
2014
影响因子：
4
通讯作者：
Ju J
中科院分区：
文献类型：
--
作者：
Fesler A;Zhai H;Ju J
在过去的十年里，非编码microRNA(MiRNA)领域的癌症研究工作一直在呈指数级增长。基于miRNA的疗法已经在临床前和临床环境中进行了测试，基于miRNA的癌症诊断和预后已经进入临床，以帮助更好地管理癌症治疗。越来越多的证据表明miRNA-129在胃肠道肿瘤中发挥重要作用，包括胃肠癌、结直肠癌、肝细胞癌和食道癌。在这篇综述中，我们专注于积累证据，证明miRNA-129在肿瘤发生、疾病进展、化疗耐药、增殖和细胞周期控制中发挥关键作用。了解miRNA-129在肿瘤中的作用和机制将有助于我们实现其治疗和诊断/预后的潜力。
In the last decade, cancer research efforts in the field of noncoding microRNA (miRNA) have been growing exponentially. miRNA-based therapeutics have been tested in both preclinical and clinical settings, and miRNA-based cancer diagnostics and prognostics have moved into clinics to help better manage cancer treatment. A growing body of evidence in recent literature suggests miRNA-129 plays important roles in gastrointestinal cancer, including gastric, colorectal, hepatocellular carcinoma, and esophageal cancer. In this review, we focus on accumulating evidence demonstrating the key roles that miRNA-129 plays in tumorigenesis, disease progression, chemoresistance, proliferation, and cell cycle control. Understanding the emerging roles and mechanisms of miRNA-129 in cancer will help us realize the therapeutic and diagnostic/prognostic potential.